Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies

References

• Cartwright RA, Watkins G. Epidemiology of Hodgkin's disease: a review. Hematol Oncol. 2004;22(1):11–26. doi:10.1002/hon.723.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-9.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Bartlett NL. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood. 2018;131(15):1698–1703. doi:10.1182/blood-2017-09-772681.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189. doi:10.1200/JCO.2011.38.0410.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Horowitz S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016;27(7):1317–1323. doi:10.1093/annonc/mdw169.
   PubMed Web of Science ®Google Scholar
• Keeping S, Wu E, Chan K, et al. Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. Expert Rev Hematol. 2018;11(6):503–511. doi:10.1080/17474086.2018.1475226.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89–99. doi:10.1186/s13643-021-01626-4.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9–22. doi:10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Zhang T. How to compare summary estimates of different subgroups in meta-analysis. Chinese J Evid-Based Med. 2017;17(12):1465–1470.
   Google Scholar
• Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33(15):2521–2537. doi:10.1002/sim.6111.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients With relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704. doi:10.1200/JCO.2015.65.9789.
   PubMed Web of Science ®Google Scholar
• Armand P, Kuruvilla J, Michot JM, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–2622. doi:10.1182/bloodadvances.2019001367.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Burton C, Radford J, et al. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood Adv. 2021;5(17):3387–3396. doi:10.1182/bloodadvances.2021004511.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Herrera AF, Domingo-Domenech E, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(21):2401–2409. doi:10.1182/blood.2019004701.
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660–ee70. doi:10.1016/S2352-3026(20)30221-0.
   PubMed Web of Science ®Google Scholar
• Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427–438. doi:10.1182/blood.2020009178.
   PubMed Web of Science ®Google Scholar
• Lepik KV, Mikhailova NB, Kondakova EV, et al. A study of safety and efficacy of nivolumab and bendamustine (NB) in patients With relapsed/refractory hodgkin lymphoma after nivolumab monotherapy failure. HemaSphere. 2020;4(3):e401–ee01. doi:10.1097/HS9.0000000000000401.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435–e002467. doi:10.1136/jitc-2021-002435.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-Up of the multicohort single-Arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439. doi:10.1200/JCO.2017.76.0793.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Terui Y, Yamamoto K, et al. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Jpn J Clin Oncol. 2020;50(11):1265–1273. doi:10.1093/jjco/hyaa117.
   PubMed Web of Science ®Google Scholar
• Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–29. doi: 10.1182/blood.2019000215.
   PubMed Web of Science ®Google Scholar
• Robert C, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153. doi: 10.1182/blood.2019000324.
   PubMed Web of Science ®Google Scholar
• Song Y, Gao Q, Zhang H, et al. Tislelizumab for relapsed/refractory classical hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis. Clin Cancer Res. 2022;28(6):1147–1156. doi:10.1158/1078-0432.CCR-21-2023.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu Y, Dong L, et al. Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with hodgkin lymphoma Who progressed or relapsed after PD-1 blockade monotherapy. Clin Cancer Res. 2021;27(10):2782–2791. doi:10.1158/1078-0432.CCR-21-0133.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang C, Li X, et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. J Immunother Cancer. 2021;9(4):e002347–e002357. doi:10.1136/jitc-2021-002347.
   PubMed Web of Science ®Google Scholar
• Song Y, Wu J, Chen X, et al. A single-Arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical hodgkin lymphoma. Clin Cancer Res. 2019;25(24):7363–7369. doi:10.1158/1078-0432.CCR-19-1680.
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–e19. doi:10.1016/S2352-3026(18)30192-3.
   PubMed Web of Science ®Google Scholar
• Lin N, Zhang M, Bai H, et al. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. Eur J Cancer. 2022;164:117–126. doi:10.1016/j.ejca.2021.07.021.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Shah G, Schöder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021;39(28):3109–3117.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(4):512–524. doi:10.1016/S1470-2045(21)00005-X.
   PubMedGoogle Scholar
• Herrera AF, Chen RW, Palmer J, et al. PET-Adapted nivolumab or nivolumab plus ICE As first salvage therapy in relapsed or refractory hodgkin lymphoma. Blood. 2019;134:239–242. doi:10.1182/blood-2019-123162.
   PubMedGoogle Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Si Z, Zhang S, Yang X, et al. The association between the incidence risk of peripheral neuropathy and PD-1/PD-L1 inhibitors in the treatment for solid tumor patients: A systematic review and meta-analysis. Front Oncol. 2019;9:866–875. doi:10.3389/fonc.2019.00866.
   PubMed Web of Science ®Google Scholar
• Mikami T, Liaw B, Asada M, et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135–144. doi:10.1007/s11060-020-03687-2.
   PubMed Web of Science ®Google Scholar
• Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. J Peripheral Nervous Syst. 2019;24(Suppl 2):S74–S85. doi:10.1111/jns.12339.
   PubMedGoogle Scholar
• Möhn N, Beutel G, Gutzmer R, et al. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy—Review of the literature and future outlook. J Clin Med. 2019;8(11):1777–1791. doi:10.3390/jcm8111777.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM. Biomarkers for immunotherapy toxicity: Are cytokines the answer? Clin Cancer Res. 2019;25(5):1452–1454. doi:10.1158/1078-0432.CCR-18-3858.
   PubMed Web of Science ®Google Scholar
• Vogrig A, Muñiz-Castrillo S, Farina A, et al. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. J Neurol 2022;269(3):1701–1714. doi:10.1007/s00415-021-10870-6.
   PubMed Web of Science ®Google Scholar
• Eisenbud L, Ejadi S, Mar N. Development of carpal tunnel syndrome in association with checkpoint inhibitors. J Oncol Pharm Pract. 2021;27(3):764–765. doi:10.1177/1078155220950430.
   PubMed Web of Science ®Google Scholar
• Montes G, Duval F, Eldani C, et al. Esophageal achalasia induced by ipilimumab and nivolumab combination: A rare neurological manifestation of immune-related autonomic neuropathy. J Immunotherapy. 2021;44(9):348–350. doi:10.1097/CJI.0000000000000381.
   PubMed Web of Science ®Google Scholar
• Zhang B, Qi L, Wang X, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond). 2020;40(12):711–720. doi:10.1002/cac2.12119.
   PubMed Web of Science ®Google Scholar
• Tian Z, Yang Y, Yang J, et al. Safety and efficacy of PD-1 inhibitors plus chemotherapy in advanced soft tissue sarcomas: A retrospective study. Cancer Manag Res. 2020;12:1339–1346. doi:10.2147/CMAR.S237300.
   PubMed Web of Science ®Google Scholar
• Yang W, Xing X, Yeung SJ, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(1):e003497–e003507. doi:10.1136/jitc-2021-003497.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Chirila RM, Dronca RS. Immune checkpoint inhibitor toxicities. Mayo Clin Proc. 2019;94(7):1321–1329. doi: 10.1016/j.mayocp.2019.03.012.
   PubMed Web of Science ®Google Scholar
• Tahir SA, Gao J, Miura Y, et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci USA. 2019;116(44):22246–22251. doi:10.1073/pnas.1908079116.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–6060. doi:10.1158/1078-0432.CCR-16-1320.
   PubMed Web of Science ®Google Scholar
• Palmieri DJ, Carlino MS. Immune checkpoint inhibitor toxicity. Curr Oncol Rep. 2018;20(9):72–83. doi:10.1007/s11912-018-0718-6.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-Related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients With melanoma treated With ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33(28):3193–3198. doi: 10.1200/jco.2015.60.8448.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Asimakopoulos JV, Konstantopoulos K, et al. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Ther Adv Hematol. 2020;11:1–31. doi:10.1177/2040620720902911.
   Web of Science ®Google Scholar
• Zinzani PL, Sasse S, Radford J, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Crit Rev Oncol Hematol. 2016;104:65–70. doi:10.1016/j.critrevonc.2016.04.019.
   PubMed Web of Science ®Google Scholar
• Cui P, Li R, Huang Z, et al. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC. Sci Rep. 2020;10(1):13160–13166. doi:10.1038/s41598-020-70207-7.
   PubMed Web of Science ®Google Scholar
• Torasawa M, Yoshida T, Yagishita S, et al. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis. Lung Cancer. 2022;167:49–57. doi:10.1016/j.lungcan.2022.03.020.
   PubMed Web of Science ®Google Scholar
• Casadei B, Argnani L, Morigi A, et al. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience. Hematol Oncol. 2020;38(5):737–741. doi:10.1002/hon.2803.
   PubMed Web of Science ®Google Scholar
• Pianko MJ, Moskowitz AJ, Lesokhin AM. Immunotherapy of lymphoma and myeloma: facts and hopes. Clin Cancer Res. 2018;24(5):1002–1010. doi:10.1158/1078-0432.CCR-17-0539.
   PubMed Web of Science ®Google Scholar
• Bai B, Wang XX, Gao Y, et al. Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2021;56(5):1151–1158. doi:10.1038/s41409-020-01164-y.
   PubMed Web of Science ®Google Scholar